A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA

Registry ID

I4V-MC-JAIO

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ELI LILLY CANADA INC

Start date

2025-02-28

Last update

2023-06-15

Conditions

• ALOPECIA AREATA

Related clinical trials

• A PHASE 2, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PROOF OF CONCEPT STUDY TO INVESTIGATE EFFICACY AND SAFETY OF LY4005130 IN ADULT PARTICIPANTS WITH SEVERE ALOPECIA AREATA
• A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBI-CONTROLLED, PROOF-OF-CONCEPT TRIAL WITH PART B OPEN-LABEL EXTENSION OF ADX-914 FOR THE TREATMENT OF SEVERE ALOPECIA ARESTA (SIGNAL-AA)
• A PHASE 1B/2A, INTRAINDIVIDUAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF ALD-102 SOLUTION FOR INTRADERMAL INJECTION IN SUBJECTS WITH ALOPECIA AREATA
• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, 3- ARM, MULTINATIONAL, MULTICENTER, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AMLITELIMAB MONOTHERAPY BY SUBCUTANEOUS INJECTION IN ADULT PARTICIPANTS WITH SEVERE ALOPECIA AREATA
• A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED 60- WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REZPEGALDESLEUKIN IN TREATMENT OF SEVERE TO VERY SEVERE ALOPECIA AREATA IN ADULT PATIENTS (REZOLVE-AA)
• A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PROGRAM TO EVALUATE EFFICACY AND SAFETY OF UPADACITINIB IN ADULT AND ADOLESCENT SUBJECTS WITH SEVERE ALOPECIA AREATA

View on source registry